REPROCELL Wins MSCRF Award to Advance Hypoimmune iPSC Platforms

Scientist in a cleanroom representing REPROCELL hypoimmune iPSC platform manufacturing

What happens when cell therapy needs to reach more patients, but manufacturing and immune compatibility still act like locked gates? That is the tension behind REPROCELL’s new Commercialization Award from the Maryland Stem Cell Research Fund, which will support work on hypoimmune iPSC platforms for clinical applications.1 This is not a flashy promise about a […]